A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

Conditions

Hepatorenal Syndrome Type 1

What is the purpose of this trial?

This study is designed to evaluate the efficacy and safety of intravenous Lucassin® (terlipressin) versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in subjects receiving standard of care albumin therapy.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Ikaria
Dates:
September 2010
Last Updated:
March 12, 2014
Study HIC#:
1009007343

Clinicaltrials.gov ID: NCT01143246